Czigléczki Gábor, Sinkó Dániel, Benkő Zsolt, Bagó Attila, Fedorcsák Imre, Sipos László
Országos Klinikai Idegtudományi Intézet, Budapest.
Semmelweis Egyetem, Idegsebészeti Tanszék, Budapest.
Ideggyogy Sz. 2019 May 30;72(5-6):153-158. doi: 10.18071/isz.72.0153.
Glioblastoma, WHO grade IV is the most frequent primary malignant brain tumor in adults. There are few articles and result about the efficacy of bevacizumab monotherapy. The aim of our paper is to examine the effect of bevacizumab therapy on progression free and overall survival in an extended database of recurrent glioblastoma patients.
In our retrospective study, patients with recurrent glioblastoma treated with bevacizumab had been collected. All of our patients received first line chemo-irradiation according the Stupp protocol treatment. The histological diagnosis was primary or secondary glioblastoma in every patient. The prognostic features of primary and secondary glioblastomas were statistically analyzed.
Eighty-six patients were selected into the retrospective analysis. The histological diagnosis was primary glioblastoma in 65 patients (75.6%) and secondary glioblastoma in 21 patients (24.4%). The mean follow up period was 36.5 months. The mean second progression free survival beside bevacizumab therapy was 6.59 months and the mean overall survival was 24.55 months. In secunder glioblastoma cases, the mean second progression free survival was 6.16 months and the mean overall survival was 91.94 months.
The bevacizumab therapy is a safe option in recurrent glioblastoma patients. Bevacizumab therapy has a positive effect both on progression free and overall survival and our results confirm the findings in the literature. There is no statistically significant difference in the second progression free survival between glioblastoma subtypes.
世界卫生组织IV级胶质母细胞瘤是成人中最常见的原发性恶性脑肿瘤。关于贝伐单抗单药治疗疗效的文章和结果较少。本文的目的是在一个扩大的复发性胶质母细胞瘤患者数据库中研究贝伐单抗治疗对无进展生存期和总生存期的影响。
在我们的回顾性研究中，收集了接受贝伐单抗治疗的复发性胶质母细胞瘤患者。我们所有的患者均按照Stupp方案接受一线化疗放疗。每位患者的组织学诊断为原发性或继发性胶质母细胞瘤。对原发性和继发性胶质母细胞瘤的预后特征进行了统计学分析。
86例患者被纳入回顾性分析。组织学诊断为原发性胶质母细胞瘤65例（75.6%），继发性胶质母细胞瘤21例（24.4%）。平均随访期为36.5个月。除贝伐单抗治疗外，平均第二次无进展生存期为6.59个月，平均总生存期为24.55个月。在继发性胶质母细胞瘤病例中，平均第二次无进展生存期为6.16个月，平均总生存期为91.94个月。
贝伐单抗治疗对复发性胶质母细胞瘤患者是一种安全的选择。贝伐单抗治疗对无进展生存期和总生存期均有积极作用，我们的结果证实了文献中的发现。胶质母细胞瘤亚型之间的第二次无进展生存期无统计学显著差异。
